Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Accounts Payables (2024 - 2025)

Xilio Therapeutics' Accounts Payables history spans 2 years, with the latest figure at $2.3 million for Q3 2025.

  • For Q3 2025, Accounts Payables rose 136.63% year-over-year to $2.3 million; the TTM value through Sep 2025 reached $2.3 million, up 136.63%, while the annual FY2024 figure was $2.6 million, N/A changed from the prior year.
  • Accounts Payables for Q3 2025 was $2.3 million at Xilio Therapeutics, down from $4.1 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $4.1 million in Q2 2025 and bottomed at $746000.0 in Q1 2024.